Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q3 2025 Earnings Report

BioVie logo
$1.52 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.47 -0.05 (-3.22%)
As of 05/22/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioVie EPS Results

Actual EPS
-$1.50
Consensus EPS
-$3.20
Beat/Miss
Beat by +$1.70
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q3 2025
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
Sunday, May 11, 2025
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q3 2025 Quarterly reportQuarterly report
(10-Q)

BioVie Earnings Headlines

Contrasting Cassava Sciences (NASDAQ:FLNA) & BioVie (NASDAQ:BIVI)
May 25 at 5:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30799480
BioVie completes final patient visit in Parkinson's drug trial
May 19, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1092525?snapi
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
 |  Porter & Company (Ad)
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/biovie-announces-completion-of-phase-2-sunrise-pd-trial-in-early-stage-parkinson-s-disease-1036171234
BioVie Inc. Completes Final Patient Visit in SUNRISE-PD Phase 2 Trial for Bezisterim in Early-Stage Parkinson's Disease
May 18, 2026  |  quiverquant.comQ
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296537/0/en/biovie-announces-completion-of-phase-2-sunrise-pd-trial-in-early-stage-parkinson-s-disease.html
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit.

In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices.

Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.

View BioVie Profile
Earnings Tools